ImmunityBio (NASDAQ:IBRX) PT Raised to $6.00 at Piper Sandler

ImmunityBio (NASDAQ:IBRX) had its target price upped by Piper Sandler from $5.00 to $6.00 in a report published on Monday morning, Benzinga reports. They currently have a neutral rating on the stock.

ImmunityBio Price Performance

IBRX stock opened at $8.54 on Monday. ImmunityBio has a 1-year low of $1.25 and a 1-year high of $10.53. The business has a fifty day moving average price of $5.40 and a 200-day moving average price of $4.33. The stock has a market capitalization of $5.78 billion, a P/E ratio of -7.36 and a beta of 1.23.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Tuesday, March 19th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.01). The company had revenue of $0.14 million during the quarter, compared to the consensus estimate of $0.03 million. As a group, analysts anticipate that ImmunityBio will post -0.68 earnings per share for the current year.

Institutional Trading of ImmunityBio

Several large investors have recently modified their holdings of the company. Tower Research Capital LLC TRC grew its holdings in shares of ImmunityBio by 43.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,393 shares of the company’s stock worth $47,000 after acquiring an additional 2,844 shares during the period. Amalgamated Bank grew its holdings in shares of ImmunityBio by 21.9% in the fourth quarter. Amalgamated Bank now owns 17,752 shares of the company’s stock worth $89,000 after acquiring an additional 3,186 shares during the period. Victory Capital Management Inc. grew its holdings in shares of ImmunityBio by 25.8% in the fourth quarter. Victory Capital Management Inc. now owns 17,642 shares of the company’s stock worth $89,000 after acquiring an additional 3,613 shares during the period. Courier Capital LLC grew its holdings in shares of ImmunityBio by 33.3% in the first quarter. Courier Capital LLC now owns 20,000 shares of the company’s stock worth $107,000 after acquiring an additional 5,000 shares during the period. Finally, Wealth Effects LLC grew its holdings in ImmunityBio by 11.2% during the fourth quarter. Wealth Effects LLC now owns 59,500 shares of the company’s stock valued at $299,000 after purchasing an additional 6,000 shares during the period. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies.